Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Puma Biotechnology Q3 2026 Results: Net Income $5.96M, Down 32.7% YoY

Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026, driven primarily by NERLYNX product sales. While the company remained profitable with a net income of $6.0 million, this was a decrease from $8.8 million in the prior year's third quarter due to higher research and development expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue55.154.5
Profit before tax6.29.2
Net income6.08.8
EPS (diluted, $ a share)$0.11$0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-32.7%
Revenue, year on year+1.1%
Operating margin9.6%
Source

10-Q filed with the SEC, NASDAQ: PBYI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Puma Biotechnology, Inc.: key numbers

Share price
$7.34Close, Nov 16
Market cap
$379M
Shares outstanding
51.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Puma Biotechnology, Inc.

All →
7:36 PM ET Form 4
Insider Selling

Puma Biotechnology Insider Michael Patrick Miller Sells $121K of Stock

Michael Patrick Miller sold 15,000 shares of Puma Biotechnology, Inc. at $8.10 a share, worth $121K in total on Nov 11, 2026. Shares held after the trade: 66,000 (-18.5%).

Value
$121K
Shares
15,000
Price
$8.10
Holding change
-18.5%
Trade date
Nov 11, 2026
4:17 PM ET 8-K
Financial Results

Puma Biotechnology Financial Results

Puma Biotechnology reported Q3 2026 financial results with total product revenue of $54.1 million, driven by sales of NERLYNX. The company reported GAAP net income of $6.0 million and raised its full-year 2026 net income guidance while continuing to advance its alisertib clinical development programs.

Term
Q3 2026

“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter.”

Alan H. Auerbach, Chairman, Chief Executive Officer and President

“We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA® clinical development programs.”

Alan H. Auerbach, Chairman, Chief Executive Officer and President
9:14 PM ET Form 4
Insider Selling

Puma Biotechnology Insider Troy Edward Wilson Sells $45.5K of Stock

Troy Edward Wilson sold 5,000 shares of Puma Biotechnology, Inc. at $9.10 a share, worth $45.5K in total on Sep 14, 2026. Shares held after the trade: 54,750 (-8.4%).

Value
$45.5K
Shares
5,000
Price
$9.10
Holding change
-8.4%
Trade date
Sep 14, 2026
9:07 PM ET Form 4
Insider Selling

Puma Biotechnology Insider Alessandra Cesano Sells $567K of Stock

Alessandra Cesano sold 62,150 shares of Puma Biotechnology, Inc. at $9.12 a share, worth $567K in total on Sep 14, 2026. Shares held after the trade: 56,700 (-52.3%).

Value
$567K
Shares
62,150
Price
$9.12
Holding change
-52.3%
Trade date
Sep 14, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.